As expected, the ratio of UBC13 low-expression accounted for 75.75% (28/37) in the chemoresistant ovarian cancer tissues, and in contrast, only 35.3% (12/34) was present in chemosensitive tissues (Fig. 2a; Table 1), with a significant difference (P = 0.001). Here, UBE2N is linked to ovarian cancer.